ERBB2 and urinary bladder carcinoma: The potential of T-DM1, as an anti-HER2 targeted therapy, to improve the efficacy of platinum-based chemotherapy in MIBC PDXs models with a low level of HER2 expression offers an exciting opportunity in the treatment of bladder cancer with even low HER2 expression.